27.04.2015 15:00:30
|
PRA is Named International Clinical Company of the Year
- Clinical Research Associate: Charlotte Holmes
- Project Manager: Silvia Casellas
- Clinical Team Leader: Emma Lewis
- Clinical Team: Sarah Gage, Ashley King, Katy Mercer, Jo Perry
PRA was also recognized with five Silver awards and one Bronze.
"PRA is delighted to receive these awards," said Sean Leech, Executive Vice President, PRA Health Sciences. "This recognition is a testament to the caliber and talent of all our dedicated employees and we are immensely proud of their accomplishments."
Organized by PharmaTimes, the International Clinical Researcher of the Year competition is considered a key barometer of quality standards in the clinical research industry. The competition is judged by independent clinical research experts and is designed to "recognize, encourage and inspire professionalism in tomorrow's leaders."
In the 2015 competition PRA competed against finalists from 22 pharmaceutical companies and clinical research organizations from around the world. The Clinical Researcher of the Year Americas award ceremony is scheduled for June 4, 2015 in Raleigh, North Carolina. PRA is well represented with 17 finalists.
ABOUT PRA HEALTH SCIENCES
PRA Health Sciences is one of the world's leading global contract research organizations, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. At PRA, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs. PRA has more than 11,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions(TM) model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. PRA has worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50+ such drugs.
CONTACT: MEDIA INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications EMAIL: rogerschristine@prahs.com PHONE: +1 919.786.8463 INVESTOR INQUIRIES: InvestorRelations@prahs.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PRA Health Sciences via Globenewswire
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu PRA Health Sciences Incmehr Nachrichten
Keine Nachrichten verfügbar. |